SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to speculation surrounding its potential inclusion in the S&P 500, sparking bullish sentiment and driving conversations about the potential "index effect" and forced ETF buying. The community is actively discussing strategies around options and covered calls, while also weighing the potential for a "sell the news" reaction post-inclusion. Some are comparing Robinhood to other stocks that were added to the S&P 500.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as traders discuss the potential for inclusion in the S&P 500, though sentiment is mixed. The community debates whether it deserves inclusion as a bitcoin proxy, with some suggesting its fate is tied to bitcoin's price action, while others eye a potential sell-off if it's excluded. Discussions also involve covered call strategies and comparisons to other stocks added to the index.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around upcoming airdrops and staking opportunities. The coin's growing watcher count and bullish sentiment are fueling discussions about potential market cap milestones and ongoing buy contests. Community members express excitement about the project's long-term vision, developments and transparency.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending due to its impending addition to the S&P 500, driving forced ETF buying and increased liquidity, though some traders are anticipating a short-term pullback following the inclusion. Community discussions revolve around the potential for new all-time highs and the long-term implications of S&P 500 membership, with some skepticism regarding short reports from firms like Muddy Waters.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as the community rallies around its unique rewards system, which distributes Solana ($SOL.X) directly to holders, regardless of price fluctuations. Recent discussions highlight the strength and resilience of the community, with many emphasizing that holding $IMG.X provides passive income superior to traditional investments, while also mentioning a new partnership with Kimbo Slice Jr.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group Inc. is trending as the community debates the impact of its recent reverse stock split and a closed investment deal with Uber. While some investors express optimism about the company's technology and long-term potential, others are concerned about cash burn and dilution, contributing to a volatile stock price. Discussions also revolve around the company's management and future prospects within the competitive EV sector.

THE COQ FATHER BOSS

$BOSSCOQ.X is trending as the community discusses its potential and compares it to other meme coins. The coin is being mentioned alongside other crypto symbols, indicating interest in its growth within the meme coin sector. Community members are actively expressing their preference for $BOSSCOQ.X over similar coins.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF ($MSTY) is trending as investors discuss its recent performance, particularly in relation to MicroStrategy ($MSTR) and Bitcoin. Concerns are emerging regarding NAV erosion and the sustainability of dividend payouts, with some community members expressing bearish sentiment. Others remain optimistic, viewing dips as buying opportunities and emphasizing the potential for high yield and long-term gains, especially if $MSTR is included in the S&P 500.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is trending as investors discuss the potential impact of warrant conversions, with some expressing frustration over the company's language regarding possible acquisitions. The community is also weighing oversold signals, awaiting news catalysts, and debating the stock's short-term direction amid broader discussions about solid-state battery technology and market manipulation. Some traders express bullish sentiment while others remain skeptical, citing past performance and management decisions.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue is trending due to reports linking Tylenol use during pregnancy to autism, sparking debate among investors and drawing attention to potential legal ramifications. While some dismiss the claims as overblown and see a buying opportunity, others express concern and anticipate further declines. Community discussions also involve the stock's dividend yield and potential recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Craig-Hallum initiated coverage of Immunome (IMNM) on Friday with a ‘Buy’ rating and a $26 price target, noting that the shares could trade up 45% or more in the firm's bull cases.The target implies an upside of about 165% from the stock’s closing price on Thursday. Shares of the company rose 7% at the time of writing.Heading into Varegacestat's late-stage topline data in desmoid tumors due in the second half and IM-1021's early-stage go/no-go proof of concept data in hematological and solid tumors late in the year or in early 2026, the firm believes these catalysts "skew risk/reward to the upside" and sees an attractive entry point, as per TheFly.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IMNM">IMNM stock</a> stayed within ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:575/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_05_at_9_42_56_AM_png_dda0252eb1.webp" alt="IMNM's Sentiment Meter and Message Volume as of 9:45 a.m. ET on Sept. 5, 2025 | Source: Stocktwits" width="575" height="59"><figcaption>IMNM's Sentiment Meter and Message Volume as of 9:45 a.m. ET on Sept. 5, 2025 | Source: Stocktwits</figcaption></figure> In August, Immunome said that it expects to report data from a late-stage study of Varegacestat “before the end of 2025” and that it is “well-positioned” to support a new drug application for it. &nbsp;The investigational drug received an Orphan Drug Designation from the U.S. Food and Drug Administration in November 2023. The designation is granted to a drug or biological product intended to prevent, diagnose, or treat a rare disease or condition, and Varegacestat aims to treat desmoid tumors, a rare, locally aggressive growth in the body's fibrous connective tissue.As for IM-1021, the company said last month that patients were recently dosed at the third dose level in an early-stage dose-escalation trial.According to data from Koyfin, all ten analysts covering IMNM rate it either ‘Buy’ or ‘Strong Buy’. The stock has an average price target of $23.56.IMNM stock is down 2% this year and approximately 26% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-biontech-rising-pre-market-today/chwIXnPRdqb">Why Did BioNTech Stock Surge 10% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’

Craig-Hellum’s price target of $26 represents an upside of about 165% from the stock’s closing price on Thursday.

Equity

Craig-Hellum’s price target of $26 represents an upside of about 165% from the stock’s closing price on Thursday.


Agios Pharmaceuticals, Inc. (AGIO) announced on Thursday that the U.S. Food and Drug Administration has extended the review period for its drug Pyrukynd, intended for the treatment of adult patients with thalassemia, by three months.Thalassemia is a rare, inherited blood disease that affects the production of the protein hemoglobin in red blood cells. By disrupting hemoglobin production, thalassemia reduces the number of circulating red blood cells and shortens their lifespan, resulting in anemia, fatigue, and severe complications.While the FDA was initially expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.agios.com/news-releases/news-release-details/agios-provides-update-us-pdufa-goal-date-pyrukyndr-mitapivat">expected</a> by December 7. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AGIO">AGIO stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:585/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_04_at_10_30_42_AM_png_307a186918.webp" alt="AGIO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on Sept. 4, 2025 | Source: Stocktwits" width="585" height="62"><figcaption>AGIO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on Sept. 4, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that these are circumstances beyond the company's control.<stembedurl>https://stocktwits.com/forprofit12/message/627455227</stembedurl>A pessimistic user, however, called for selling the company's shares.<stembedurl>https://stocktwits.com/Jadek6/message/627455837</stembedurl>In the original application, the company had described the risk of hepatocellular injury with the drug. However, the firm stated on Thursday that it has submitted a proposed Risk Evaluation and Mitigation Strategy (REMS) in response to a recent information request from the agency.The extension in date of the FDA’s decision is not the result of new or additional efficacy or safety data requested by the FDA or submitted by Agios, but a result of the new REMS submission, the company said. It further termed the REMS submission a major amendment to its original application.“We remain confident in the favorable benefit-risk profile of PYRUKYND in thalassemia,” said CEO Brian Goff. &nbsp;As per Agios, approximately 6,000 adult patients are diagnosed with thalassemia in the U.S.BofA subsequently lowered its price target on Agios Pharmaceuticals to $51 from $52 while keeping a ‘Buy’ rating on the shares. The firm noted that the extension was not the result of new data requested by the FDA or submitted by the company. BofA still views approval in thalassemia as likely given its key opinion leader checks and the strength of data from late-stage trials supporting the application. As such, Agios remains one of the firm's top picks even with the delay, it said.Pyrukynd is already approved for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. Pyruvate kinase (PK) deficiency is a rare, inherited disorder causing chronic hemolytic anemia in adults, where red blood cells break down too quickly due to a lack of the PK enzyme, resulting in low red blood cell count.AGIO stock is up by 6% this year but down by over 22% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/fda-says-no-advisory-commitee-meeting-required-for-aquestive-oral-epinephrine-film/chwd20pRdYB">FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More 

While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7. 

Novavax, Inc. (NVAX) announced on Thursday that its COVID-19 vaccine, Nuvaxovid, has been approved in Japan, triggering a milestone payment from Japanese pharmaceutical company Takeda.The vaccine was approved for initial immunization (first and second vaccinations) in individuals aged six years or older, and as a booster immunization (following the third vaccination) in individuals aged 12 years or older in the country.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> stayed within ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.Under Novavax’s <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.novavax.com/press-releases/2025-09-04-Nuvaxovid-R-Now-Approved-in-Japan-Triggering-Takeda-Milestone-Payment">deal</a> with Takeda, the company is also eligible to receive royalties on net sales of Nuvaxovid from Takeda in this vaccination season. The company did not disclose specific payment amounts, saying that it is bound by contractual confidentiality agreements.Novavax and Takeda updated the terms of their 2020 collaboration and licensing agreement for Nuvaxovid in May. The amended deal includes an upfront payment, a payment related to the 2024-2025 season, annual milestones associated with regulatory approvals, and royalties on net sales earned every season moving forward, the company stated. In the second quarter, the company reported $27 in licensing, royalties, and other revenue from Takeda.Novavax got the U.S. Food and Drug Administration’s approval for Nuvaxovid in May for the prevention of COVID-19 in adults 65 years and older and individuals aged 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from the disease. The FDA then requested the company to conduct a postmarketing commitment (PMC) study.However, Novavax <a href="https://stocktwits.com/news-articles/markets/equity/novavax-cfo-says-sanofi-to-cover-majority-of-future-nuvaxovid-study-costs/chrScEpRd50">stated</a> last month that the study will not impact its operating profit for 2025, as its partner, Sanofi, will cover the majority of the expenses.NVAX stock is down 9% this year and approximately 38% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/this-burger-chain-stock-has-gained-9-this-year-bmo-capital-sees-another-14-upside/chwdEPGRdYl">This Burger Chain Stock Has Gained 9% This Year And BMO Capital Sees Another 14% Upside – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax COVID-19 Vaccine Approved In Japan, Triggers Milestone Payment From Partner Takeda

The vaccine was approved for initial immunization in individuals aged six years or older and as a booster immunization in those aged 12 years or older in the country. 

Aquestive Therapeutics (AQST) on Thursday said that the U.S. Food and Drug Administration has informed the Company that an advisory committee meeting is not required for Anaphylm Sublingual Film.Anaphylm Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. It is similar in size to a postage stamp and begins to dissolve on contact. No water or swallowing is required for administration.According to Aquestive, Anaphylm has the potential to be the first and only orally delivered epinephrine product for the treatment of severe allergic reactions in the U.S., doing away with the need for injections. The FDA is expected to decide on Aquestive’s application for approval of the sublingual film by January 31, 2026.Aquestive CEO Dan Barber <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-fda-will-not-require-advisory">said</a> that the company is encouraged by the FDA’s decision to waive a meeting and added that the company is “well-positioned” for launch. Shares of the company traded 17% higher in the premarket session.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AQST">AQST stock</a> stayed within ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels. A Stocktwits user opined that the stage is now set for approval of Anaphylm.<stembedurl>https://stocktwits.com/BioAmerica/message/627450441</stembedurl>Last month, Aquestive <a href="https://stocktwits.com/news-articles/markets/equity/aquestive-therapeutics-enters-75-million-dollar-funding-agreement/chsRkEVRdOO">said</a> that it entered into a $75 million strategic funding agreement with funds managed by RTW Investments, LP. The financing will become available upon approval of Anaphylm by the FDA and satisfaction of certain refinancing and other customary conditions. Barber said that the financing will support the company through 2027 and allow it to successfully bring Anaphylm to market.RTW, meanwhile, will receive a tiered single-digit percentage of annual net sales of Anaphylm in the U.S. for the treatment of type I allergic reactions, including anaphylaxis, subject to a cap.AQST stock is up by 11% this year but down by about 7% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/ethereum-outperforms-bitcoin-while-broader-crypto-market-slips/chwd22IRdYJ">Ethereum Outperforms Bitcoin, While Broader Crypto Market Slips</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film

 The FDA is expected to decide on Aquestive’s application for approval of the sublingual film by January 31, 2026. 

Shares of Wave Life Sciences (WVE) tumbled over 19% on Wednesday after the company announced that its WVE-006 led to RNA editing in all participants treated in a trial evaluating the therapy as a treatment for alpha-1-antitrypsin deficiency (AATD).AATD is an inherited genetic disorder that reduces the production of the AAT protein, which is crucial for protecting the lungs and liver. It is caused by a genetic mutation, and WVE-006 is designed to address the manifestations of AATD by correcting the mutation.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-positive-update-ongoing">announced</a> on Wednesday that WVE-006 resulted in RNA editing in all treated participants, with durable production of serum AAT at levels associated with a lower risk of liver and lung disease following repeat 200 mg doses.Despite the impressive first demonstration of a dynamic acute phase response post-RNA editing in alpha-1-antitrypsin deficiency, Wave Life's stock performance suggests the Street expected a greater increase in AAT protein, Leerink said. Leerink raised its price target on Wave Life Sciences to $26 from $24 and kept an ‘Outperform’ rating on the shares.Leerink further thinks investors should take advantage of this weakness to buy the stock ahead of additional important catalysts, which it remains optimistic investors will appreciate despite today's confusion.H.C. Wainwright analyst Andrew Fein, meanwhile, said Wave’s stock decline despite the “encouraging” data was an “overreaction.” The analyst stated that these results strengthen the firm's conviction that WVE-006 can deliver both lung and liver benefits, and the firm believes the current data, excluding the 400 mg multiple ascending dose data, "still shows an approval endpoint.” The analyst has a ‘Buy’ rating and $22 price target on Wave Life Sciences shares.Data from both the 200 mg and 400 mg single-dose cohorts support a monthly or less frequent subcutaneous dosing regimen, Wave Life Sciences said. Dosing is ongoing in the 400 mg multidose cohort with a monthly dosing regimen, for which Wave expects to deliver data in the first quarter of 2026. Further, all adverse events observed in the study were mild to moderate in intensity, and there were no serious adverse events or discontinuations, it added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/WVE">WVE</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_03_at_2_24_05_PM_png_6c95483e4e.webp" alt="WVE's Sentiment Meter and Message Volume as of 2:24 p.m. ET on Sept. 3, 2025 | Source: Stocktwits" width="623" height="59"><figcaption>WVE's Sentiment Meter and Message Volume as of 2:24 p.m. ET on Sept. 3, 2025 | Source: Stocktwits</figcaption></figure>GSK has the exclusive global license for WVE-006. Development and commercialization responsibilities will transfer to GSK after Wave completes the study. Wave is eligible for up to $525 million in milestone payments, as well as tiered royalties on net sales, for WVE-006.WVE stock is down 37% this year but up approximately 40% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-reports-near-four-percent-jump-in-us-vehicle-sales-in-august/chwT6RHRd8r">Ford Reports Near 4% Jump In US Vehicle Sales In August</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Why

Wave Life Sciences said Wednesday that its therapy WVE-006 successfully edited RNA in all trial participants, producing lasting levels of a key protein tied to lower risks of liver and lung disease after repeat 200 mg doses.

Shares of Tectonic Therapeutic (TECX) soared about 6% in Wednesday’s pre-market after Oppenheimer initiated coverage of the company with an ‘Outperform’ rating.Oppenheimer has an $80 price target on Tectonic, representing an upside of over 380% from the stock’s closing price on Tuesday. The firm stated that it likes the prospects of Tectonic's lead asset, TX45, for addressing prevalent and progressive cardiovascular disorders that are currently inadequately treated.The analyst is optimistic ahead of next year's mid-stage study data readout in pulmonary hypertension with heart failure with preserved ejection fraction, which it believes could pave the way for a multi-billion-dollar global sales opportunity, according to TheFly.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TECX">Tectonic</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_03_at_7_02_32_AM_png_aa449b866b.webp" alt="TECX's Sentiment Meter and Message Volume as of 7:02 a.m. ET on Sept. 3, 2025 | Source: Stocktwits" width="577" height="62"><figcaption>TECX's Sentiment Meter and Message Volume as of 7:02 a.m. ET on Sept. 3, 2025 | Source: Stocktwits</figcaption></figure>Tectonic shares closed down 35% on Tuesday following Eli Lilly's (LLY) data presentation and publication from its failed study in heart failure patients with preserved ejection fraction using a recombinant long-acting relaxin mimetic, Volenrelaxin. Tectonic’s lead candidate also seeks to treat similar cardiovascular disorders.According to Truist analyst Danielle Brill, the negative news "represents another hit to the emerging relaxin class of drugs." Still, the firm also notes that read-through should be limited as the population enrolled in Lilly's trial is distinct from those enrolled in Tectonic's.The firm, which believes Tectonic's approach to targeting Combined Post- and Pre-Capillary Pulmonary Hypertension has "the strongest rationale" and calls the selloff "overdone," maintained a ‘Buy’ rating and a $64 price target on Tectonic shares.TECX stock is down by 64% this year and by about 13% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cybersecurity-vendor-zscaler-s-stock-rises-premarket-what-s-fueling-upside/chwTMR0Rd89">Cybersecurity Vendor Zscaler’s Stock Rises Premarket: What’s Fueling The Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate

Oppenheimer stated that it likes the prospects of Tectonic's lead asset, TX45, to address prevalent and progressive cardiovascular disorders that are inadequately treated.

TG Therapeutics, Inc. (TGTX) on Wednesday stated that its board of directors has authorized a new share repurchase program to acquire up to an additional $100 million of the company’s common stock.The new share repurchase authorization follows the company's completion of its previously authorized $100 million share repurchase program, initially announced in August 2024. Under the previous program, TG Therapeutics repurchased a total of approximately 3.5 million shares of its common stock at an average price of $28.55 per share. CEO Michael S. Weiss <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase">said</a> that the company repurchased $78 million of the stock in August alone at “highly attractive prices.”TGTX stock gained nearly 2% in Wednesday’s pre-market.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TGTX">TGTX stock</a> stayed within ‘bearish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘low’ levels.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase">said</a> on Wednesday that repurchases under the new program may be made on a time-to-time basis through open market purchases, privately negotiated transactions, or other means.Weiss said that the new repurchase program reflects the company’s conviction that “current market prices do not adequately reflect the multibillion-dollar potential of Briumvi or the long-term growth prospects of TG Therapeutics.”Briumvi is a medication used to treat relapsing forms of multiple sclerosis (MS) in adults. Multiple Sclerosis is a chronic, often disabling, autoimmune disease that affects the brain and spinal cord, disrupting communication between the brain and other parts of the body. The disease symptoms include difficulty walking, blurred vision, and altered sensations in limbs or face.In the <a href="https://stocktwits.com/news-articles/markets/equity/tg-therapeutics-stock-tumbles-after-disappointing-q2-but-company-reaffirms-confidence-in-multiple-sclerosis-drug/chrXrTDRdcR">second quarter</a>, Briumvi’s net product revenue totaled $138.8 million, representing 91% growth over the same period last year and accounting for over 98% of the company’s total revenue.TGTX stock is down 1% this year but up approximately 31% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tectonic-stock-soars-pre-market-after-tuesday-sell-off/chwTUeNRd8m">Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 TG Therapeutics Board Authorizes New $100M Share Repurchase Program

The new share repurchase authorization follows the company's completion of its previously authorized $100 million share repurchase program, initially announced in August 2024.

Zymeworks Inc. (ZYME) on Tuesday announced its decision to discontinue clinical development of ZW171, designed to target certain cancers.ZW171 is designed to address cancers driven by Mesothelin, a cell-surface protein overexpressed in certain cancers, including gynecological, thoracic, and digestive system cancers. The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer.At the time of writing, <a href="https://stocktwits.com/symbol/ZYME">ZYME stock</a> was down by over 17% in Tuesday’s pre-market session. On Stocktwits, retail sentiment around ZYME stock, however, rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:655/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_8_57_28_AM_png_feb9611316.webp" alt="ZYME's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="655" height="61"><figcaption>ZYME's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure>After establishing a maximum tolerated dose in the early-stage trial, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-decision-discontinue-clinical-development">determined</a> that further dose escalation would be unlikely to support a benefit-risk profile consistent with the company’s intent to develop it as a standalone therapy.While ongoing participants in the trial will continue treatment at the discretion of their investigator, participants who have discontinued treatment will continue safety follow-up as per the study protocol, Zymeworks said.Zymeworks CEO Kenneth Galbraith said that the outcome is “disappointing” given the promising preclinical activity observed with ZW171.“We continue to advance our broader product pipeline, including the ongoing Phase 1 trial of ZW191 and the initiation of a Phase 1 study for ZW251 expected in 2025. We are also preparing an IND filing for ZW209, our DLL3-directed trispecific T cell engager, planned in the first half of 2026,” he added.&nbsp;ZYME stock is up by 1% this year and nearly 29% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/merck-investigational-drug-shows-reduction-in-cholestrol-in-late-stage-trial/chv6ol3Rdnp">Merck’s Investigational Drug Shows Reduction In Cholesterol In Late-stage Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update

The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer.

Bumble (BMBL) CEO Wolfe Herd and team are reportedly building a new, AI-powered matchmaking app.The Wall Street Journal <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/tech/ai/whitney-wolfe-herd-bumble-ai-398779bb?mod&amp;#61;Searchresults&amp;pos&amp;#61;1&amp;page&amp;#61;1">reported</a> on Friday that Bumble has consulted psychologists and relationship counselors to program a matchmaking AI. The company plans to launch a beta version of the app to select users this fall, according to the report, which notes that it will be separate from the existing Bumble app.Shares of the company traded nearly 1% lower by Friday noon. On Stocktwits, retail sentiment about <a href="https://stocktwits.com/symbol/BMBL">BMBL stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The goal behind the AI-powered matchmaking app is to create “the world’s smartest and most emotionally intelligent matchmaker in existence,” the report said, citing Herd. The new app aims to help users build a dating profile based on how they answer questions about past relationships, breakups, and experiences with love and dating, according to the report. It will be built as a large language model, communicating with users in a humanlike way.The team is unsure of how many matches the system will generate, and the monetization strategy is still being determined, the report said. However, users might also have to pay for each match, it said.Once it is ready, the new app will get to know the user over multiple sessions, make a dating profile for them, find them matches, and help book reservations for a date, the report said. BMBL stock is down 23% this year and approximately 5% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nukkleus-to-form-joint-venture-with-israel-based-mandragola/chtTmaPRdNN">Nukkleus Stock Shot Up A Whopping 37% Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

The exterior of Bumble Headquarters on July 15, 2024 in Austin, Texas. (Photo by Brandon Bell/Getty Images)

Bumble Developing AI-Powered Matchmaking App: Report

 According to The Wall Street Journal, the company plans to launch a beta version of the app to select users this fall, which will be separate from the existing Bumble app. 

The U.S. Food and Drug Administration (FDA) announced on Thursday that it is withdrawing its approval of the new drug application (NDA) for Amylyx Pharmaceuticals’ (AMLX) Relyvrio.Amylyx has voluntarily requested that the FDA withdraw approval of this application and has waived its opportunity for a hearing, the agency <a target="_blank" rel="noopener noreferrer nofollow" href="https://public-inspection.federalregister.gov/2025-16646.pdf">said</a>. The FDA approved the application for Relyvrio for the treatment of amyotrophic lateral sclerosis (ALS) in adults in September 2022. Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, is a progressive, fatal neurodegenerative disorder that causes muscle weakness and paralysis by destroying motor neurons, the cells that control voluntary muscle movement.&nbsp;However, last year, the company reported to the agency that a late-stage trial evaluating the drug in patients living with ALS did not meet its prespecified goals. It also notified the agency that it plans to discontinue marketing of Relyvrio as of Oct. 31, 2024.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AMLX">AMLX stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels. Shares of the company traded 1% lower at the time of writing.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_28_at_2_17_49_PM_png_ec4ad4caa5.webp" alt="AMLX's Sentiment Meter and Message Volume as of 2:18 p.m. ET on Aug. 28, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>AMLX's Sentiment Meter and Message Volume as of 2:18 p.m. ET on Aug. 28, 2025 | Source: Stocktwits</figcaption></figure>Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company <a href="https://stocktwits.com/news-articles/markets/equity/amylyx-discontinues-investigative-therapy-program-in-rare-neurological-disorder/chsUG7LRdkv">reiterated</a> earlier this week that it has a cash runway until the end of 2026 on the heels of discontinuing its AMX0035 program in adults living with progressive supranuclear palsy.The decision to discontinue the program was made after it failed to show differences compared to the placebo on primary or secondary outcomes at week 24 in a mid-stage trial. The company will not initiate the late-stage portion of the program, it then said.AMLX stock is up 148% this year and approximately 349% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/li-auto-announces-lower-q3-delivery-outlook-despite-new-vehicle-launches/chs60e1RdZ2">Li Auto Announces Lower Q3 Delivery Outlook Despite New Vehicle Launches: Retail Sees i8, i6 Selling Like ‘Hot Cakes’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target

Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a cash runway until the end of 2026.

Current Price	$40.26
Prev Close	$40.07
Open	$40.31
Dividend Yield	N/A
50-Day Moving Average	$39.38
Beta	N/A
Avg. Volume	6,458.95
PE Ratio	N/A

52-Week High	$49.18
52-Week Low	$34.29
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

IWMW
iShares Russell 2000 BuyWrite ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWMW News

IWMW iShares Russell 2000 BuyWrite ETF